Applied Therapeutics, Inc. december 4, 2024 Please complete the form below to contact Kaplan Fox regarding the Applied Therapeutics, Inc. Investigation: Join a Case First Name * Last Name * Email Address * Phone Number * Ticker Symbol Or Company Name * Please Insert Your Estimation Of Losses In USD * Are you a current or former employee of the company mentioned having traded above? * Yes No Captcha Submit If you are human, leave this field blank. Principle Contacts Pamela MayerPMayer@kaplanfox.comLaurence D. KingLKing@kaplanfox.com Kaplan Fox & Kilsheimer LLP is Investigating Applied Therapeutics, Inc. (APLT) for Potential Securities Law Violations Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQ: APLT). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are an Applied Therapeutics investor and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003. On November 27, 2024, after the markets closed, the Company disclosed that the Food and Drug Administration (“FDA”) issued a Complete Response Letter (“CRL”) for its new drug application for govorestat, AT-007-1002, for treatment of classic galactosemia (the “NDA”). The Company’s press release states that the “CRL indicate[d] that the FDA completed its review of the application and determined that it is unable to approve the NDA in its current form, citing deficiencies in the clinical application.” On Friday, November 29, 2024, the first trading day following the news, Applied Therapeutics stock fell $6.54 per share, over 76%, to close at $2.03 per share on heavy trading volume. Then, on December 2, 2024 after the markets closed, the Company disclosed in a Form 8-K filing that following issuance of the CRL, the Company received a warning letter limited to the AT-007-1002 study and that the warning letter identified issues relating to “electronic data capture” and a “dosing error in the dose-escalation phase of the study resulting in slightly lower levels than targeted in a limited number of patients, which was remedied prior to achieving maintenance dosing.” WHY CONTACT KAPLAN FOX Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. If you have any questions about this investigation, please contact: Pamela A. MayerKAPLAN FOX & KILSHEIMER LLP800 Third Avenue, 38th FloorNew York, New York 10022(646) 315-9003pmayer@kaplanfox.com Laurence D. KingKAPLAN FOX & KILSHEIMER LLP1999 Harrison Street, Suite 1560Oakland, California 94612(415) 772-4704lking@kaplanfox.com Connect with Kaplan Fox. Receive a complimentary case review now. Contact Us Celsius Holdings, Inc. See the Case Dentsply Sirona Inc. See the Case Western Asset Macro Opportunities Fund See the Case Franklin Resources, Inc. See the Case Customers Bancorp, Inc. See the Case Rentokil Initial plc See the Case Warner Bros Discovery, Inc. See the Case Applied Therapeutics, Inc. See the Case Zeta Global Holdings Corp. See the Case Macy’s, Inc. See the Case Quanterix Corp See the Case MediaAlpha, Inc. See the Case
